Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study.
Li Xu(Shanghai Jiao Tong University), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Rong Guo(Sun Yat-sen University), Xinhao Xiong(Sun Yat-sen University), Qiaoxuan Wang(Institute of Polymers), Jian‐Hong Zhong(Tumor Hospital of Guangxi Medical University), Lie Zheng(Sun Yat-sen University), Wei Dai(Fujian Medical University), Wei Wei(Zhujiang Hospital), Rongce Zhao(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Lianghe Lu(Sun Yat-sen University), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse)
Cited by 0
Related Papers
Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
|Journal of Hepatology|2018|559
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216